Ghent University Academic Bibliography

Fatal HLH as a complication of treating secondary histiocytic sarcoma with trametinib and chemotherapy

Yoni Aelvoet (UGent) , Ruben Van Paemel (UGent) , Mattias Hofmans (UGent) , Karl Vandepoele (UGent) , Annelynn Wallaert (UGent) , David Creytens (UGent) , Jo Van Dorpe (UGent) , Siebe Loontiens (UGent) , Joni Van der Meulen (UGent) , F. J. Bautista, et al.

(2026) BELGIAN JOURNAL OF HEMATOLOGY. 17(4). p.239-245

Add to list

Implementing EWOG-MDS clinical guidelines for juvenile myelomonocytic leukaemia in Belgium

C. Geurten, G. Levy, P. Mazilier, A. Uyttebroeck, C. Piette and Barbara De Moerloose (UGent)

(2026) BELGIAN JOURNAL OF HEMATOLOGY. 17(2). p.84-91

Add to list

Prime-time for IncRNA signatures in acute myeloid leukaemia?

Z Ren, Barbara De Moerloose (UGent) and Tim Lammens (UGent)

(2025) BELGIAN JOURNAL OF HEMATOLOGY. 16(2). p.54-64

Add to list

The role of UBTF-TD mutations in paediatric acute myeloid leukaemia and myelodysplastic syndrome

B Decuyper, I Andriessen, Mattias Hofmans (UGent) and Barbara De Moerloose (UGent)

(2025) BELGIAN JOURNAL OF HEMATOLOGY. 16(4). p.152-159

Add to list

Journal Article
A2
open access

Precision medicine in relapsed and refractory paediatric haematological malignancies and the role of an international tumour board

Alexandra Reekmans (UGent) , Uri Ilan, Judith M Boer, Tim Lammens (UGent) , Steven Goossens, C Michel Zwaan, Monique L den Boer and Barbara De Moerloose (UGent)

(2024) BELGIAN JOURNAL OF HEMATOLOGY. 15(7). p.263-268

Add to list

Journal Article
A2
open access

Practice guidelines for the therapeutic drug monitoring of asparaginase in acute lymphoblastic leukemia

Veerle Mondelaers (UGent) , Tim Lammens (UGent) , Martijn de Jong (UGent) , Larissa Deneweth (UGent) , Katrien Vandemeulebroecke (UGent) and Barbara De Moerloose (UGent)

(2022) BELGIAN JOURNAL OF HEMATOLOGY. 13(6). p.236-242

Add to list

Epidemiology of COVID-19 infections in haematology patients and prognostic factors for outcome : a national, multicentre retrospective study

T Mercier, S Fieuws, K Theunissen, MC Ngirabacu, N Straetmans, C Spilleboudt, Dominiek Mazure (UGent) , V De Wilde, A De Becker, D Selleslag, et al.

(2022) BELGIAN JOURNAL OF HEMATOLOGY. 13(7). p.269-276

Add to list

PARTNER-project : a model and tools to support shared decision making in relapsed/refractory multiple myeloma (RRMM) treatment

Lauren Sillis, Ann Van Hecke (UGent) and Veerle Foulon

(2021) BELGIAN JOURNAL OF HEMATOLOGY. 12(7). p.305-317

Add to list

Journal Article
A2
open access

Current developments and hurdles in CAR-T cell therapy for acute myeloid leukaemia

Laurens Van Camp (UGent) , Tim Lammens (UGent) , Anne Uyttebroeck and Barbara De Moerloose (UGent)

(2021) BELGIAN JOURNAL OF HEMATOLOGY. 12(6). p.244-250

Add to list

Novel therapeutic targets in juvenile myelomonocytic leukaemia : are noncoding RNAs valuable treatment options?

Mattias Hofmans (UGent) , Tim Lammens (UGent) , Jan Philippé (UGent) and Barbara De Moerloose (UGent)

(2021) BELGIAN JOURNAL OF HEMATOLOGY. 12(4). p.173-176

Academic Bibliography

Fatal HLH as a complication of treating secondary histiocytic sarcoma with trametinib and chemotherapy

Implementing EWOG-MDS clinical guidelines for juvenile myelomonocytic leukaemia in Belgium

Prime-time for IncRNA signatures in acute myeloid leukaemia?

The role of UBTF-TD mutations in paediatric acute myeloid leukaemia and myelodysplastic syndrome

Precision medicine in relapsed and refractory paediatric haematological malignancies and the role of an international tumour board

Practice guidelines for the therapeutic drug monitoring of asparaginase in acute lymphoblastic leukemia

Epidemiology of COVID-19 infections in haematology patients and prognostic factors for outcome : a national, multicentre retrospective study

PARTNER-project : a model and tools to support shared decision making in relapsed/refractory multiple myeloma (RRMM) treatment

Current developments and hurdles in CAR-T cell therapy for acute myeloid leukaemia

Novel therapeutic targets in juvenile myelomonocytic leukaemia : are noncoding RNAs valuable treatment options?

Contents

Support

Contact